CD40LG and COVID-19: While some studies reported positive EBV DNA in plasma of COVID‐19 patients and confirmed EBV reactivation by conducting serological tests for antibodies against VCA IgM and early antigen‐diffuse EA‐D IgG as well as antibodies against the latent EBNA‐1 [20, 22], there are only case reports of IM due to EBV in COVID‐19 patients, including in an immunocompromised patient [23] and a 4‐year‐old child [24].